Multiomics Analysis Reveals the Impact of Microbiota on Host Metabolism in Hepatic Steatosis

• Published in: Advanced science Vol. 9; no. 11; pp. e2104373 - n/a
• Main Authors: Zeybel, Mujdat, Arif, Muhammad, Li, Xiangyu, Altay, Ozlem, Yang, Hong, Shi, Mengnan, Akyildiz, Murat, Saglam, Burcin, Gonenli, Mehmet Gokhan, Yigit, Buket, Ulukan, Burge, Ural, Dilek, Shoaie, Saeed, Turkez, Hasan, Nielsen, Jens, Zhang, Cheng, Uhlén, Mathias, Borén, Jan, Mardinoglu, Adil
• Format: Journal Article
• Language: English
• Published: Germany John Wiley & Sons, Inc 01.04.2022; John Wiley and Sons Inc; Wiley
• Subjects: Body mass index; Clinical Medicine; Datasets; Diabetes; Diseases; dysbiosis; Dysbiosis - genetics; fatty liver; Fatty Liver - genetics; Fatty liver disease; Gastrointestinal Microbiome; Gastrointestinal Microbiome - genetics; genetics; Gut and oral metagenomic; gut and oral metagenomics; Hepatic steatosis; human; Humans; intestine flora; Klinisk medicin; Liver diseases; Magnetic resonance imaging; metabolic dysfunction-associated fatty liver disease; Metabolic syndrome; Metabolism; metabolomics; Metagenomics; Microbiome; Microbiota; Microbiota - genetics; microflora; Molecular biology; Multiomic analyse; multiomics analysis; Obesity; Pathogenesis; Plasma; Proteomics; Regression analysis; Statistical analysis; System medicine; systems biology; systems medicine; systems biology; metabolic dysfunction-associated fatty liver disease; proteomics; metabolomics; systems medicine; gut and oral metagenomics; multiomics analysis

Metabolic dysfunction‐associated fatty liver disease (MAFLD) is a complex disease involving alterations in multiple biological processes regulated by the interactions between obesity, genetic background, and environmental factors including the microbiome. To decipher hepatic steatosis (HS) pathogene...